Laboratory biomarkers and frailty: presentation of the frailomic initiative

by G. Lippi, P. Jansen-Duerr, J. Viña, A. Durrance-Bagale, I. Abugessaisa, D. Gomez-Cabrero, J. Tegnér, J. Grillari, J. Erusalimsky, A. Sinclair, L. Rodriguez-Manãs, FRAILOMIC consortium
Year:2015

Bibliography

Laboratory biomarkers and frailty: presentation of the frailomic initiative
G. Lippi, P. Jansen-Duerr, J. Viña, A. Durrance-Bagale, I. Abugessaisa, D. Gomez-Cabrero, J. Tegnér, J. Grillari, J. Erusalimsky, A. Sinclair, L. Rodriguez-Manãs, FRAILOMIC consortium
Clinical Chemistry and Laboratory Medicine, 1;53(10): e253-5 2015

Abstract

​Frailty is traditionally defined as a specific geriatric syndrome characterized by increased vulnerability to unfavorable outcomes, such as falls, disability, hospitalization and overall mortality, which is a result of the impairment of manifold and interrelating biological pathways, ultimately leading to decreased homoeostatic reserve and lower resistance to stressor events, such as therapy or infections . Due to an increasing trend toward ageing of the population (the percentage of people aged ≥ 65 years is projected to increase by 20% in Europe by 2060), frailty will soon emerge as a serious and increasingly important global health burden.

DOI: https://doi.org/10.1515/cclm-2015-0147

Keywords

Ageing Biomarkers Frailty Sarcopenia
KAUST

"KAUST shall be a beacon for peace, hope and reconciliation, and shall serve the people of the Kingdom and the world."

King Abdullah bin Abdulaziz Al Saud, 1924 – 2015

Contact Us

  • 4700 King Abdullah University of Science and Technology

    Thuwal 23955-6900, Kingdom of Saudi Arabia

     

Quick links

© King Abdullah University of Science and Technology. All rights reserved